

27 May 2015

Stephanie So
Senior Advisor, Listings
ASX Compliance Pty Ltd
20 Bridge Street
Sydney NSW 2000

Appendix 3Y


Dear Stephanie,

Enclosed with this letter is an Appendix 3Y with respect to the exercise of options under the Pharmaxis Employee Option Plan by the Company's CEO, Mr Gary Philips.

Due to an administrative oversight the Company did not file an Appendix 3Y within the requisite period of time.

The Company is aware of its obligations and confirms it has adequate arrangements in place to ensure it is able to meet its disclosure obligations.

Yours faithfully



Mr David McGarvey
Chief Financial Officer/ Company Secretary

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	PHARMAXIS LTD
ABN	75 082 811 630

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Gary Jonathan Phillips
Date of last notice	26 February 2015

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
Date of change	18 May 2015
No. of securities held prior to change	Ordinary shares: 60,000 Options over ordinary shares: 2,522,500
Class	Ordinary shares
Number acquired	1,030,000
Number disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil
No. of securities held after change	Ordinary shares: 1,090,000 Options over ordinary shares: 1,492,500

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of options under Pharmaxis Ltd Employee Option Plan
---	--

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.